In the first quarter of this year, Nanjing’s biopharmaceutical industry demonstrated strong growth with notable achievements.

These include the approval of 20 newly listed drug product specifications, as well as 14 new drug clinical trials and 43 newly approved Class II medical devices.

Additionally, there were a total of 16 investment and financing events, resulting in an impressive total amount of approximately 4.066 billion yuan and a growth rate of 65.7% for supply-side enterprises.

Nanjing’s biomedical-related scientific and educational resources, as well as its abundant human resources, have played a significant role in bolstering the quantitative and qualitative increase of innovative products within the city’s biomedical industry.

In 2022, Nanjing’s biopharmaceutical industry had revenues of 182.12 billion yuan, up 12 per cent. What’s more, there are 54 newly approved drugs for marketing in the city, accounting for 26% of the total in Jiangsu.

According to the 2022 China Biomedical Industrial Park Competitiveness Evaluation and Analysis Report, three key industrial parks, including Nanjing Biotech and Pharmaceutical Valley, Nanjing Jiangning Hi-Tech Development Zone and Nanjing Economic and Technological Development Zone, all entered the top 30.

Moreover, Nanjing has built 166 innovation platforms, which cover various types of biopharmaceuticals, including drug screening, animal experiments, and other key aspects of new drug creation. These platforms serve as crucial infrastructures for supporting the city’s thriving biomedical industry.

Overall, the robust growth of Nanjing’s biopharmaceutical industry, together with its abundance of high-quality scientific and educational resources and human talent, is positioning the city as a leading player in China’s rapidly expanding biomedical sector.